Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis

References

• Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131(23):2528–2540.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicenter, retrospective analysis. Lancet Oncol. 2016;17(3):389–400.
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Bunworasate U, Julamanee J, et al. Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin lymphoma in older patients: the result of the nationwide multi-institutional registry Thai Lymphoma Study Group. J Geriatr Oncol. 2020;11(1):62–68.
   PubMed Web of Science ®Google Scholar
• Su C, Nguyen KA, Bai HX, et al. Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients. Leuk Lymphoma. 2018;59(6):1406–1412.
   PubMed Web of Science ®Google Scholar
• Cheson B, Fisher R, Barrington S, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon SE, Kim W. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. J Hematol Oncol. 2018;11(1):140.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–2980.
   PubMed Web of Science ®Google Scholar
• Dong LH, Zhang LJ, Wang WJ, et al. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma. Leuk Lymphoma. 2016;57(7):1600–1606.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and l-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119(2):348–355.
   PubMed Web of Science ®Google Scholar
• Li JW, Li YJ, Zhong MZ, et al. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: a multicenter retrospective study. Eur J Haematol. 2018;100(3):247–256.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of “sandwich” l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118(13):3294–3301.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang M, Xie L, et al. Five-year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer Med. 2016; 5(1):33–40.
   PubMed Web of Science ®Google Scholar
• Wang H, Wuxiao ZJ, Zhu J, et al. Comparison of gemcitabine, oxaliplatin and l-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2015;56(4):971–977.
   PubMed Web of Science ®Google Scholar
• Wei W, Wu P, Li L, et al. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematology. 2017;22(6):320–329.
   PubMed Web of Science ®Google Scholar
• Bi XW, Xia Y, Zhang WW, et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol. 2015;94(9):1525–1533.
   PubMed Web of Science ®Google Scholar
• Bi XW, Jiang WQ, Zhang WW, et al. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchememotherapeutic radiotherapy. Ann Hematol. 2015;94(7):1175–1184.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–4416.
   PubMed Web of Science ®Google Scholar
• Ding H, Chang J, Liu LG, et al. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study. Int J Hematol. 2015;102(2):181–187.
   PubMed Web of Science ®Google Scholar
• Wang JH, Wang L, Liu CC, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget. 2016;7(20):29092–29101.
   PubMedGoogle Scholar
• Wang JJ, Dong M, He XH, et al. GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Medicine. 2016;95(6):e2787.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85.
   PubMed Web of Science ®Google Scholar
• Leal AD, Allmer C, Maurer MJ, et al. Variability of performance status assessment between patients with hematologic malignancies and their physicians. Leuk Lymphoma. 2018;59(3):695–701.
   PubMed Web of Science ®Google Scholar
• Xie W, Hu K, Xu F, et al. Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: a retrospective analysis of 252 cases. Mol Clin Oncol. 2013;1(5):911–917.
   PubMedGoogle Scholar